ESSA Pharma Inc (TSX-V: EPI)(NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, reported yesterday its financial results for the year ended 30 September 2018.
The company reported a net loss of USD11.6m for the year ended 30 September 2018, compared to a net loss of USD4.5m in the year-ago period.
The firm posted research and development expenditures for the year ended 30 September 2018 at USD4.9m net of grants compared to USD5.7m net of grants for the year ended 30 September 2017.
Cash on hand at 30 September 2018, was USD14.8m, with working capital of USD12.3m, reflecting the aggregate gross proceeds of the completed January 2018 financing, which totalled USD26m.
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis